Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001406 · ClinicalTrials.gov registry record
Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia
A clinical trial of Immune System Diseases and Hypersensitivity, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 800
- Enrollment target
- 1
- Study location
NCT00001406: Recruiting study of Immune System Diseases and Hypersensitivity, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00001406 is a study of Immune System Diseases and Hypersensitivity that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 800 participants, above the 108-participant average among 18 other Immune System Diseases trials with a reported enrollment target (641% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001406, a study of Immune System Diseases and Hypersensitivity, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate how, why and under what conditions eosinophils (a type of white blood cell) become activated and will examine their function in immune reactions. Eosinophil counts often rise in response to allergies, asthma, and parasitic worm infections. They can also go up in uncommon autoimmune conditions and, rarely, in association with tumors. Elevated levels of these cells is called eosinophilia. Usually, eosinophilia causes no apparent symptoms, but in rare cases there may be local swelling and itching, allergic lung problems, heart disease or nerve damage caused by the release of toxic substances in these cells into body tissues. Patients 1 to 100 years of age with eosinophil counts greater than 750/ml or an abnormal accumulation of eosinophils in the skin or body tissues may be eligible for this study. All participants will have a thorough medical history, physical examination and blood tests. Depending on the person's age and symptoms, other diagnostic tests may be done, including specialized studies of the eye, lungs, skin, bone marrow, nerves or heart. This is not a treatment study, and no experimental treatments will be offered. Patients who require treatment will receive standard medical care. Certain other procedures may be requested solely for research purposes. All participants will be asked to donate extra blood for laboratory studies investigating how immune cells and other immune substances in the blood act to stimulate a rise in eosinophils. In addition, some participants may undergo one or more of the following: * Annual Follow-up evaluations - Physical examinations and blood tests to evaluate changes in the patient's condition and eosinophil counts over time. * Bone marrow biopsy and aspiration will be recommended during the initial evaluation, and in certain patients at other times when it is important to look directly at the newly developing cells in the bone marrow. For this procedure an area of skin and bone is anesthetized
Primary Outcome
Identification and characterization of clinical and genetic variants of hypereosinophilic syndromes.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 1997-04-21 |
What NCT00001406 shows while recruiting
NCT00001406 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 108-participant average among 18 other Immune System Diseases trials with a reported enrollment target (641% higher).
The record links to 5 conditions, with Immune System Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT00001406 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00001406 about?
NCT00001406 is a clinical study titled "Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia". This study will investigate how, why and under what conditions eosinophils (a type of white blood cell) become activated and will examine their function in immune reactions. Eosinophil counts often rise in response to allergies, asthma, and parasitic worm infections. They can also go up in uncommon ...
What is the current status of trial NCT00001406?
This trial is currently recruiting. The enrollment target is 800 participants. The study started on 1997-04-21.
What conditions does trial NCT00001406 study?
This clinical trial studies the following conditions: Immune System Diseases, Hypersensitivity, Eosinophilia, Helminthiasis, Parasitic Disease.
Who is sponsoring clinical trial NCT00001406?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001406 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune System Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001406's enrollment target sits among peer trials
800 1st of 18 higher than 18 of 18 other Immune System Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Immune System Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
RECRUITING · Phase 2
-
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
RECRUITING · Phase 2
-
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
RECRUITING
-
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
RECRUITING · Phase 2
-
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI